A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
4actual
Sites
9
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-11 | actual | When the study began enrolling |
| Primary completion | 2025-07-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-14 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non Small Cell Lung Cancer
- Bladder Cancer
- Renal Cell Carcinoma
- Melanoma
- Head and Neck Cancer
- Colorectal Cancer
Interventions
- Biological: PF-07921585
- Biological: Sasanlimab — also filed as PF-06801591
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Dose-Limiting Toxicity (DLT) (Parts 1 and 2)
measured Baseline up to Cycle 2 (each cycle is 21 days)
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious AEs (Parts 1 and 2)
measured Baseline up to 28 days after the last dose of PF-07921585 or after 90 days after the last dose of sasanlimab
Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities (Parts 1 and 2)
measured Baseline up to 28 days after the last dose of PF-07921585 or after 90 days after the last dose of sasanlimab
Objective Response Rate - Percentage of Participants With Objective Response (Part 3)
measured Date of first dose up to 2 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed